An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)

Patent thicket

A large, complex, and often overlapping set of patents, typically used by a company to protect a product, sometimes making it difficult for competitors to enter the market with similar products.

Patent infringement

The act of making, using, selling, or importing a patented invention without permission from the patent owner.

Generic drug

A medication created to be the same as an already marketed brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use, but usually sold at a lower cost.

Biological product

A product like a vaccine, blood component, allergen, somatic cell, gene therapy, tissue, or recombinant therapeutic protein, regulated by the FDA. Biosimilar products are similar versions of existing biological products.

Patent Group

Under this bill, two or more patents that are owned by the same entity and are linked together through formal statements (disclaimers) because they are considered similar or related, often used to make them expire at the same time.

Disclaimer (under Section 253)

A legal statement filed with the patent office, often used to ensure that patents with overlapping subject matter or that are not sufficiently distinct from one another expire on the same date. The bill refers to patents linked by these disclaimers as part of a 'Patent Group'.